- Home
- Publications
- Publication Search
- Publication Details
Title
Half-life extended biotherapeutics
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 16, Issue 7, Pages 903-915
Publisher
Informa Healthcare
Online
2016-03-12
DOI
10.1517/14712598.2016.1165661
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Acting PASylated Leptin Ameliorates Obesity by Promoting Satiety and Preventing Hypometabolism in Leptin-DeficientLepob/obMice
- (2016) Florian Bolze et al. ENDOCRINOLOGY
- The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy
- (2015) Jonathan T. Sockolosky et al. ADVANCED DRUG DELIVERY REVIEWS
- A novel expression cassette delivers efficient production of exclusively tetrameric human butyrylcholinesterase with improved pharmacokinetics for protection against organophosphate poisoning
- (2015) Stanislav Terekhov et al. BIOCHIMIE
- Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
- (2015) William R. Strohl BIODRUGS
- Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
- (2015) Eric F. Zhu et al. CANCER CELL
- Protein–polymer conjugation—moving beyond PEGylation
- (2015) Yizhi Qi et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Recombinant Human Serum Albumin Fusion Proteins and Novel Applications in Drug Delivery and Therapy
- (2015) Brian Rogers et al. CURRENT PHARMACEUTICAL DESIGN
- GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects
- (2015) J. Lin et al. DIABETES OBESITY & METABOLISM
- Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency
- (2015) Orit Cohen-Barak et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Using glyco-engineering to produce therapeutic proteins
- (2015) Martina Dicker et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial
- (2015) Kathleen N. Moore et al. GYNECOLOGIC ONCOLOGY
- Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates
- (2015) R. Stidl et al. HAEMOPHILIA
- Site-Specific PEGylation of Therapeutic Proteins
- (2015) Jonathan Dozier et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Freeze-drying of HESylated IFNα-2b: Effect of HESylation on storage stability in comparison to PEGylation
- (2015) Robert Liebner et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- The cell biology of renal filtration
- (2015) Rizaldy P. Scott et al. JOURNAL OF CELL BIOLOGY
- Head to Head Comparison of the Formulation and Stability of Concentrated Solutions of HESylated versus PEGylated Anakinra
- (2015) Robert Liebner et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Half-life extended factor VIII for the treatment of hemophilia A
- (2015) A. Tiede JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Longer-acting clotting factor concentrates for hemophilia
- (2015) J. S. Powell JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity
- (2015) J. N. Mahlangu et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Pharmacokinetic properties of IgG and various Fc fusion proteins in mice
- (2015) Felix Unverdorben et al. mAbs
- A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life
- (2015) Colby A Souders et al. mAbs
- PASylation of Murine Leptin Leads to Extended Plasma Half-Life and Enhanced in Vivo Efficacy
- (2015) Volker Morath et al. MOLECULAR PHARMACEUTICS
- Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In Vivo Half-Life Extension
- (2015) Laura J. Goodall et al. PLoS One
- A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties
- (2015) Felix Unverdorben et al. PLoS One
- Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
- (2015) Angela Schoch et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics
- (2015) Steven A. Jacobs et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion
- (2015) Joe Salas et al. THROMBOSIS RESEARCH
- The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
- (2015) Maarten Van Roy et al. ARTHRITIS RESEARCH & THERAPY
- Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
- (2015) Kine Marita Knudsen Sand et al. Frontiers in Immunology
- Ziv-aflibercept (Zaltrap) for the Treatment of Metastatic Colorectal Cancer
- (2014) Scott L. Perkins et al. ANNALS OF PHARMACOTHERAPY
- Albiglutide
- (2014) Jennifer M. Trujillo et al. ANNALS OF PHARMACOTHERAPY
- A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma
- (2014) W. Wick et al. CLINICAL CANCER RESEARCH
- Protein HESylation for half-life extension: Synthesis, characterization and pharmacokinetics of HESylated anakinra
- (2014) Robert Liebner et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Albumin and its application in drug delivery
- (2014) Darrell Sleep Expert Opinion on Drug Delivery
- Enhancedin VivoEfficacy of a Type I Interferon Superagonist with Extended Plasma Half-life in a Mouse Model of Multiple Sclerosis
- (2014) Daniel Harari et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Interaction with Both Domain I and III of Albumin Is Required for Optimal pH-dependent Binding to the Neonatal Fc Receptor (FcRn)
- (2014) Kine Marita Knudsen Sand et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Extending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor (FcRn) Binding
- (2014) Jan Terje Andersen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease
- (2014) Thomas Idorn et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Applications of elastin-like polypeptides in drug delivery
- (2014) Sarah R. MacEwan et al. JOURNAL OF CONTROLLED RELEASE
- Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering
- (2014) Yuan Wang et al. JOURNAL OF DRUG TARGETING
- Therapeutic Protein–Polymer Conjugates: Advancing Beyond PEGylation
- (2014) Emma M. Pelegri-O’Day et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation
- (2014) Claudia T Mendler et al. mAbs
- Biopharmaceutical benchmarks 2014
- (2014) Gary Walsh NATURE BIOTECHNOLOGY
- Glycoengineering of Interferon-β 1a Improves Its Biophysical and Pharmacokinetic Properties
- (2014) Kyoung Song et al. PLoS One
- Protective Effect of Different Anti-Rabies Virus VHH Constructs against Rabies Disease in Mice
- (2014) Sanne Terryn et al. PLoS One
- An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein
- (2014) Johan Seijsing et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII
- (2014) Sabine Zollner et al. THROMBOSIS RESEARCH
- Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B
- (2014) Jonathan M Ducore et al. Expert Review of Hematology
- Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B
- (2014) Jerry Powell et al. Patient Preference and Adherence
- A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults
- (2013) Gabriel J. Robbie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Selective Blockade of Tumor Necrosis Factor Receptor I Inhibits Proinflammatory Cytokine and Chemokine Production in Human Rheumatoid Arthritis Synovial Membrane Cell Cultures
- (2013) Emily M. Schmidt et al. ARTHRITIS AND RHEUMATISM
- Albumin as a versatile platform for drug half-life extension
- (2013) Darrell Sleep et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Discussion about Several Potential Drawbacks of PEGylated Therapeutic Proteins
- (2013) Fan Zhang et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
- (2013) J. Mahlangu et al. BLOOD
- Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat
- (2013) Weike Bao et al. Cardiovascular Diabetology
- Aflibercept
- (2013) K. K. Ciombor et al. CLINICAL CANCER RESEARCH
- Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
- (2013) Timo Rath et al. CRITICAL REVIEWS IN BIOTECHNOLOGY
- Proinsulin-Transferrin Fusion Protein as a Novel Long-Acting Insulin Analog for the Inhibition of Hepatic Glucose Production
- (2013) Yan Wang et al. DIABETES
- Engineering a Monomeric Fc Domain Modality byN-Glycosylation for the Half-life Extension of Biotherapeutics
- (2013) Tetsuya Ishino et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection
- (2013) M. Amiram et al. JOURNAL OF CONTROLLED RELEASE
- Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein
- (2013) A. Orlova et al. JOURNAL OF NUCLEAR MEDICINE
- Pharmacokinetics of Peptide–Fc Fusion Proteins
- (2013) W.U. Benjamin et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers
- (2013) G. Golor et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins
- (2013) M. Schlapschy et al. PROTEIN ENGINEERING DESIGN & SELECTION
- A long-acting erythropoietin fused with noncytolytic human Fc for the treatment of anemia
- (2012) Se Hwan Yang et al. ARCHIVES OF PHARMACAL RESEARCH
- Atrial Natriuretic Peptide-Fc, ANP-Fc, Fusion Proteins: Semisynthesis, In Vitro Activity and Pharmacokinetics in Rats
- (2012) Adam R. Mezo et al. BIOCONJUGATE CHEMISTRY
- Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients
- (2012) E. Santagostino et al. BLOOD
- Half-life prolongation of therapeutic proteins by conjugation to ATIII-binding pentasaccharides: a first-in-human study of CarboCarrier®insulin
- (2012) André M. M. Miltenburg et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents
- (2012) Ricardo P Garay et al. Expert Opinion on Drug Delivery
- Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients
- (2012) Jochen Tuettenberg et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Selective conjugation of poly(2-ethyl 2-oxazoline) to granulocyte colony stimulating factor
- (2012) Anna Mero et al. JOURNAL OF CONTROLLED RELEASE
- Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia
- (2012) J. N. MAHLANGU et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein
- (2012) R. T. PETERS et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
- (2012) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions
- (2012) J. T. Sockolosky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A
- (2012) F. Unverdorben et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Pioneering designs for recombinant coagulation factors
- (2012) Stefan Schulte THROMBOSIS RESEARCH
- Insulin detemir for the treatment of obese patients with type 2 diabetes
- (2012) Priscilla Hollander Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- The development of romiplostim for patients with immune thrombocytopenia
- (2011) Graham Molineux Annals of the New York Academy of Sciences
- Anti-Flt1 peptide – Hyaluronate conjugate for the treatment of retinal neovascularization and diabetic retinopathy
- (2011) Eun Ju Oh et al. BIOMATERIALS
- New anticoagulants - promising and failed developments
- (2011) Job Harenberg et al. BRITISH JOURNAL OF PHARMACOLOGY
- PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery
- (2011) Paola Milla et al. CURRENT DRUG METABOLISM
- Non-immunoglobulin based protein scaffolds
- (2011) John Löfblom et al. CURRENT OPINION IN BIOTECHNOLOGY
- Strategies for extended serum half-life of protein therapeutics
- (2011) Roland E Kontermann CURRENT OPINION IN BIOTECHNOLOGY
- Modulating antibody pharmacokinetics using hydrophilic polymers
- (2011) Chen Chen et al. Expert Opinion on Drug Delivery
- Plasma Half-life Extension of Small Recombinant Antibodies by Fusion to Immunoglobulin-binding Domains
- (2011) Meike Hutt et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Neonatal Fc receptor and IgG-based therapeutics
- (2011) Timothy T. Kuo et al. mAbs
- Effects of Receptor Binding on Plasma Half-Life of Bifunctional Transferrin Fusion Proteins
- (2011) Xiaoying Chen et al. MOLECULAR PHARMACEUTICS
- Glycosylation of Therapeutic Proteins
- (2010) Ricardo J. Solá et al. BIODRUGS
- Long acting hyaluronate – exendin 4 conjugate for the treatment of type 2 diabetes
- (2010) Ji-Hyun Kong et al. BIOMATERIALS
- PEGylation of therapeutic proteins
- (2010) Simona JevsÌevar et al. Biotechnology Journal
- Prolonged activity of factor IX as a monomeric Fc fusion protein
- (2010) R. T. Peters et al. BLOOD
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Ron J. Keizer et al. CLINICAL PHARMACOKINETICS
- Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
- (2010) Wolfgang Glaesner et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Designing a Long-Acting Human Growth Hormone (hGH) by Fusing the Carboxyl-Terminal Peptide of Human Chorionic Gonadotropin β-Subunit to the Coding Sequence of hGH
- (2010) Fuad Fares et al. ENDOCRINOLOGY
- How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes
- (2010) S. Arnolds et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR
- (2010) Takuo Suzuki et al. JOURNAL OF IMMUNOLOGY
- Transferrin Fusion Technology: A Novel Approach to Prolonging Biological Half-Life of Insulinotropic Peptides
- (2010) B.-J. Kim et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Phase I/II randomised study of a novel erythropoiesis-stimulating agent (AMG 114) for the treatment of anaemia with concomitant chemotherapy in patients with non-myeloid malignancies
- (2010) Richard de Boer et al. MEDICAL ONCOLOGY
- The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein
- (2010) J. Hopp et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Fc-Based Cytokines
- (2009) Jalal A Jazayeri et al. BIODRUGS
- Strategies to Extend Plasma Half-Lives of Recombinant Antibodies
- (2009) Roland E. Kontermann BIODRUGS
- Pharmacological significance of glycosylation in therapeutic proteins
- (2009) Huijuan Li et al. CURRENT OPINION IN BIOTECHNOLOGY
- Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology
- (2009) Chichi Huang CURRENT OPINION IN BIOTECHNOLOGY
- Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
- (2009) M. A. Bush et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years
- (2009) Sven Björkman et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner
- (2009) Volker Schellenberger et al. NATURE BIOTECHNOLOGY
- Genetic fusion to albumin improves the pharmacokinetic properties of factor IX
- (2009) Hubert J. Metzner et al. THROMBOSIS AND HAEMOSTASIS
- Half-life extension through albumin fusion technologies
- (2009) Stefan Schulte THROMBOSIS RESEARCH
- Poly(2-methacryloyloxyethyl phosphorylcholine) for Protein Conjugation
- (2008) Andrew Lewis et al. BIOCONJUGATE CHEMISTRY
- Conjugation of ATIII-Binding Pentasaccharides to Extend the Half-Life of Proteins: Long-Acting Insulin
- (2008) Martin de Kort et al. ChemMedChem
- Molecular engineering and design of therapeutic antibodies
- (2008) Leonard G Presta CURRENT OPINION IN IMMUNOLOGY
- Etanercept
- (2008) Erin Ducharme et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- N-Glycosylation as Novel Strategy to Improve Pharmacokinetic Properties of Bispecific Single-chain Diabodies
- (2008) Roland Stork et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology
- (2008) B. M. Tijink et al. MOLECULAR CANCER THERAPEUTICS
- Engineering of a femtomolar affinity binding protein to human serum albumin
- (2008) A. Jonsson et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Prolonged in-vivo half-life of factor VIIa by fusion to albumin
- (2008) Thomas Weimer et al. THROMBOSIS AND HAEMOSTASIS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started